Europe’s life-sciences industry is shedding experienced people while warning that it cannot find the talent it needs. Both claims are true, and the gap between them may decide whether Europe keeps pace in biopharma innovation.
Since 2023, Bayer has cut more than 10,000 roles. Novo Nordisk announced 9,000 cuts in September 2025. Novartis is closing production lines in Switzerland and Germany. Yet the European Commission itself concedes that demand for biotech and biomanufacturing skills outstrips supply. Meanwhile, China is redesigning its universities by decree. Europe has no comparable mechanism, and time is short.
Jobs are not disappearing. They are moving.
Most restructurings pair cuts with reinvestment. Novo Nordisk is redirecting about USD 1.25 billion a year into obesity and diabetes R&D; by September 2026 its workforce was roughly 13,000 below its peak. At Stein, Novartis is cutting up to 550 tablet and capsule jobs as it shifts to automation, while investing USD 80 million in siRNA production at Schweizerhalle that will create about 80 jobs. In Basel, up to 130 roles go as small-scale biologics production closes and a new biologics development centre opens.
The pattern repeats across Europe. Hundreds of conventional manufacturing, quality and commercial roles disappear; a few dozen high-skill roles appear; and the people leaving are rarely those trained to fill them.
The cycle may be turning. In Q2 2026, 59% fewer pharma companies cut staff than a year earlier, and job postings rose 15%. The question is whether those let go will be qualified for the jobs coming back.
The skills gap is already throttling innovation
Mario Draghi’s competitiveness report found that about a quarter of EU firms struggle to hire, and 77% say even new recruits lack the competencies they need. The EU produces around 850 STEM graduates per million inhabitants a year, against more than 1,100 in the US. At its current pace it will reach 12 million ICT specialists by 2030, far short of its 20 million target.
In biopharma, the shortage sits exactly where companies are investing:
- MSAT and process development, especially for cell and gene therapies.
- Automation engineering that combines GMP experience with process control.
- Digital and AI, where Cytiva’s industry index recorded a 45% rise in talent shortages between 2023 and 2025.
- Data science, notably statistical modelling, machine learning and Python.
The cost shows up as slower technology transfer, delayed facility start-ups and stalled AI projects. Yet displaced professionals hold the hardest-to-teach ingredient: GMP discipline, regulatory literacy and deep process knowledge. Ireland’s training institute NIBRT finds such workers mostly lack only the new-technology layer. Adding it is far faster than training a graduate from scratch.
China rewires its universities
Between 2021 and 2025, China closed or suspended about 12,200 undergraduate programmes and created more than 10,200. Majors whose graduates struggle to find work receive a “yellow card”, then a “red card”. Cuts fall on management, arts and languages; growth goes to AI, intelligent manufacturing, robotics and interdisciplinary engineering. The April 2026 national catalogue added 38 majors, 13 of them with “digital”, “intelligent” or “smart” in their names.
The public record shows no mandate targeting MSAT by name, but the pivot feeds the disciplines that MSAT and digital biomanufacturing depend on. The costs are real: new curricula lag industry, and the overhaul is driven by youth unemployment as much as ambition. Europe should not copy top-down closures. It should, however, envy the feedback loop that links graduate employment to programme approval within a year or two. In Europe, that loop often takes five.
Brussels has the diagnosis, not the bridge
The Union of Skills (March 2025), the Life Sciences Strategy (July 2025) and the proposed European Biotech Act (December 2025) all name skills shortages. Three weaknesses remain.
Speed. The Biotech Act is still before Parliament and Council, and its main funding window opens only in 2028.
Target group. EU measures focus on students, researcher-entrepreneurs and talent from abroad. Mid-career professionals displaced from within the industry have no dedicated programme. The European Globalisation Adjustment Fund has rarely been used for pharma; a notable case was 700 AstraZeneca workers in Sweden in 2012.
Fragmentation. Training and unemployment support are national, and Switzerland, home to Novartis and Roche, sits outside EU programmes.
Proof that it can work
Ireland built NIBRT in 2007 as a “flight simulator” for biomanufacturing. It has trained more than 45,000 people in a simulated GMP plant, over 4,800 in 2025 alone. Through Springboard+, jobseekers study free and employees pay only 10% in shortage areas; NIBRT reports 60–70% of jobseekers moving into biopharma. When MSD closed an API site, retraining was built into the transition plan.
Sweden turned a closure into a cluster. When AstraZeneca shut its Lund research site in 2010, about 900 specialists lost their jobs. A foundation bought the campus with Lund University and Region Skåne; former AstraZeneca scientists founded contract research firms in its labs. By the end of 2013 more people worked there than when AstraZeneca left. Today Medicon Village hosts about 2,800 people in 180 organisations.
Neither model waited for Brussels.
An agenda for action
- Build regional training hubs. Replicate NIBRT in five to eight life-science regions, funded through the Biotech Act’s centres of excellence.
- Create a redeployment trigger. When an employer announces 100 or more redundancies, open funded retraining within 90 days, through a faster Globalisation Fund or Swiss cantonal equivalents.
- Publish graduate outcomes by programme. Transparency is Europe’s democratic answer to China’s yellow cards.
- Make micro-credentials portable across the EU and Switzerland, so retrained specialists can move countries.
- Modernise university offers. Launch joint MSAT, bioprocess and data-science degrees, industrial PhDs and 6–12-month conversion programmes, with displaced senior experts as adjunct faculty.
- Reskill before you release. Companies should earmark a share of restructuring savings for transition training. One per cent of Novo Nordisk’s planned DKK 8 billion in annual savings would be DKK 80 million.
- Turn closing sites into ecosystems, as Lund did, and open paid traineeships and apprenticeships to young people.
For professionals affected by restructuring, the fastest additions are Python and data analysis, process analytical technology, automation and MES basics, digital data integrity and AI literacy. Demand is strongest in contract manufacturers, biologics and advanced-therapy sites.
A window that will not stay open
Europe’s problem is not a shortage of capable people but a shortage of bridges. If experienced professionals drift out of the sector, their knowledge is lost. Retrained quickly, they are Europe’s fastest talent pipeline. Ireland and Lund show it works. The question for Brussels, Bern and national capitals is whether they act before the next wave of cuts, or after.